Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06081153 · ClinicalTrials.gov registry record · Early Phase 1
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 44
- Enrollment target
NCT06081153: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT06081153 is a Early Phase 1 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 44 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06081153, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers will compare participants receiving evolocumab injections to participants receiving placebo injections to see how the tissue and cells of the aorta are affected by changes in LDL-C levels.
Primary Outcome
IL-6 expression will be measured in myeloid cells in the aortic tissue specimens using single nucleus RNA sequencing and confirmed by whole tissue ELISA.
Interventions
- DRUG Placebo
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-12-01 |
| Est. Completion | 2029-02-28 |
| Phase | Early Phase 1 |
What is known before NCT06081153 opens enrollment
NCT06081153 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06081153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06081153 about?
NCT06081153 is a clinical study titled "Mechanistic Clinical Trial of PCSK9 Inhibition for AAA". The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers wil...
What is the current status of trial NCT06081153?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 44 participants. The study started on 2026-12-01. Estimated completion is 2029-02-28.
What interventions are being tested in trial NCT06081153?
The interventions under investigation include: Placebo (DRUG), Evolocumab (DRUG).
Who is sponsoring clinical trial NCT06081153?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06081153's enrollment target sits among peer trials
44 589th of 2000 higher than 1,401 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI